For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1208/Antithrombotic-Drugs-World-Industry-and-Market-Prospects-2014-2024

1. Antithrombotic Drugs:
World Industry and Market Prospects
2014-2024
©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

2. Contents
1.1. Executive Summary
Executive Summary
1.1 What This Report Covers
1.2 Antithrombotic Drugs: World Industry and Market Prospects 2014-2024 Overview
1.3 Chapter Outlines
1.4 Research and Analysis Methods
1.5 Glossary of Terms in this Report
2. Blood Clotting: Mechanisms, Disorders and Current Treatments
2.1 Understanding Haemostasis and Coagulation
2.2 What is Thrombosis
2.3 Complications of Thrombosis
2.3.1 Pulmonary Embolism: A Thrombus Blocking Blood Supply to the Lungs
2.3.2 Stroke Results From Blockage of Blood Flow to the Brain
2.3.3 Acute Coronary Syndrome (ACS): Blockage of Blood Supply to the Heart
2.4 Antithrombotic Drug Treatment
3. Antithrombotic Drugs: World Market 2014-2024
3.1 The World Antithrombotic Drug Market in 2012 and 2013
3.2 The World Antithrombotic Drug Market: An Overarching Revenue Forecast 2014-2024
3.3 Driving and Restraining Forces Affecting the Antithrombotic Drugs Market
3.3.1 An Increasing Patient Population Drives Market Growth
3.3.2 Intense Competition from Generics Threatens to Restrain the Market
3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue and Market Share
Predictions, 2018 and 2024
www.visiongain.com

3. Contents
3.5 The Future of the World Market for Antithrombotic Drugs by Therapeutic Class: Grouped
Revenue Forecasts, 2014-2024
3.6 Antiplatelet Drugs Were the Leading Therapeutic Class in 2012
3.7 Anticoagulant Drugs: Leading the Market from 2013 Onwards
3.7.1 Heparins: The Leading Anticoagulants of 2013, But Will This Continue?
3.7.2 Direct Thrombin Inhibitors Achieved High Growth in 2013
3.7.3 Direct Factor Xa Inhibitors: A Novel Therapeutic Class With Great Potential
3.7.4 Vitamin K Antagonists Have Led the Anticoagulant Drug Market for 60 Years
3.8 Fibrinolytics Will Continue to be a Staple of the Antithrombotic Drug Market
4. Leading National Markets 2014-2024
4.1 Which Were the Leading National Markets for Sales of Antithrombotic Drugs in 2012 and
2013?
4.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues and
Market Shares, 2018 and 2024
4.3 Which National Markets Will Grow Fastest to 2024?
4.4 The US: Dominating the Antithrombotic Drug Market from 2014-2024
4.5 The EU5: Are the Guidelines for Approval of Biosimilar LMWHs Set to Change?
4.5.1 Germany Leads the EU5
4.5.2 France: Healthcare System Reform Will Inhibit Sales Growth?
4.5.3 UK: What Does the Introduction of a Value-Based Pricing System Mean for the Market?
4.5.4 Italy’s Healthcare System – Advantages Conducive to Pharma Business
4.5.5 Spain: Reductions in Government Healthcare Spending Will Restrict Growth
4.6 Japan: The Aging Population Will Stimulate Demand for Antithrombotic Drugs from 20142024
www.visiongain.com

4. Contents
4.7 The Chinese Antithrombotic Drug Market Will Capture Market Share
4.8 The Brazilian Antithrombotic Drug Market 2014-2024: Strong Growth as Universal
Healthcare Coverage is Expanded
4.9 The Indian Antithrombotic Drug Market is Hindered by Limited Government Healthcare
Spending
4.10 The Russian Antithrombotic Drug Market: Poor Healthcare Funding Will Prevent Expansive
Growth
5. The Leading Products in the Market, 2014-2024
5.1 Plavix and Lovenox Remain the Market Leaders in 2012 and 2013, Despite Generic
Competition
5.2 The Leading Antithrombotic Drugs: Comparison of Revenue and Market Share, 2018 and
2024
5.3 Which Medicines Will Achieve the Highest Rates of Growth to 2024?
5.4 Plavix Faces Competition From 14 Generic Competitors, So What Does the Future Hold?
5.4.1 Branded Competition for Plavix?
5.5 Lovenox: Biosimilar Competition in the EU is Expected
5.6 Pradaxa Was the Leading Novel Oral Anticoagulant in 2013, but the Race is Heating Up
5.7 Xarelto Leads the Direct Factor Xa Inhibitor Market
5.8 Activase Leads the Fibrinolytics Market, With Little Competition
5.9 Effient Competes with Brilinta as well as Generic Competition for Plavix
5.10 Aspirin Cardio: The Most Lucrative Version of Acetylsalicylic Acid
5.11 Angiomax is Losing Share of the Direct Thrombin Inhibitors Market to Pradaxa
5.12 Pletal Faces Generic Competition and Restrictions on Use in Europe
5.13 Aggrenox to Face Generic Competition Earlier Than Expected in the US
www.visiongain.com

5. Contents
5.14 Sandoz’s Enoxaparin Sodium: Revenue Forecast 2014-2024
5.15 Fragmin Faces Rivalry from Generic Competition to Lovenox
5.16 Arixtra: Aspen Has Acquired Worldwide Rights from GSK
5.17 Brilinta: Facing Investigation
5.18 Eliquis: Will Late Entry to the Market Affect Uptake?
6. The Antithrombotic Drug Development Pipeline 2014-2024
6.1 The R&D Pipeline for Antithrombotic Drugs: An Overview
6.2 The Antiplatelet Drug R&D Pipeline in 2014
6.2.1 FDA Advisory Committee Has Voted in Favour of Merck’s Vorapaxar
6.2.2 Pozen is Seeking a Strategic Partner for its Antiplatelet Drug, PA32540
6.2.3 The Medicine Company’s Cangrelor Awaits Approval
6.3 The R&D Pipeline for Anticoagulants, 2014
6.3.1 Heparins: Little R&D Activity in 2014
6.3.1.1 Will Development of Momenta’s Adomiparin Continue?
6.3.1.2 The Discontinuation of Semuloparin
6.3.2 The Vitamin K Antagonist Pipeline: One Product in Development in 2014
6.3.3 Many Development Direct Thrombin Inhibitors Have Been Discontinued
6.3.4 The Direct Factor Xa Inhibitor Pipeline: Only Two Compounds Remain
6.3.4.1 Daiichi Sankyo’s Lixiani (edoxaban) Awaits Approval in the US and the EU
6.3.5 Portola Pharmaceuticals’ Betrixaban
6.3.6 Sanofi Has Discontinued Development of Otamixaban
6.4 The Fibrinolytics R&D Pipeline, 2014
6.4.1 Lundbeck’s Desmoteplase
www.visiongain.com

6. Contents
6.4.2 Bharat Biotech and ThromboGenics’ THR-100
6.5 The R&D Pipeline for Other Antithrombotic Drugs, 2013
6.5.1 Asahi Kasei Pharma America’s ART 123
6.5.2 Regado Biosciences is Developing an Anticoagulation System with an Antidote
6.5.3 Isis Pharmaceuticals’ ISIS-FXI Rx
7. Leading Companies in the Antithrombotic Drug Market
7.1 Leading Antithrombotic Drug Manufacturers in 2013
7.2 Sanofi Leads the Market, but is its Position Under Threat?
7.3 Bristol-Myers Squibb Had a Dramatic Loss of Market Share in 2013
7.4 Boehringer Ingelheim is Captures Market Share
7.5 Bayer Markets Two Antithrombotic Drugs
7.6 Johnson & Johnson Can Achieve Success With a Limited Product Portfolio
7.7 Genentech Will Retain Market Share
7.8 The Medicines Company’s Position Will be Bolstered by the Launch of its New Drug
7.9 Otsuka: A Limited Antithrombotic Drug Portfolio
7.10 Eli Lilly: Market Position is Dependent on Success of Effient
7.11 Sandoz: A Gradually Declining Share of the Market
8. Qualitative Analysis of the Antithrombotic Drug Market, 20142024
8.1 The Strengths and Weaknesses of the Antithrombotic Drug Market in 2014
8.1.1 Thrombotic Disease: Management Rather Than Cure
8.1.2 The Lack of Antidotes for the Novel Oral Anticoagulants Restricts the Market
www.visiongain.com

7. Contents
8.2 The Opportunities and Threats Facing the Market 2014-2024
8.2.1 Rising Disease Prevalence Creates Opportunities in the Market
8.2.2 Further Development of Existing Drugs
8.2.3 High Demand for Antidotes to the Novel Oral Anticoagulants
8.2.4 The Threat of Generic Competition
8.2.5 High Level of Competition is a Threat to New Entrants - What Can Developers Do?
8.2.6 High Risk of Investment in New Drug Development
8.2.7 Healthcare Budget Pressures Threaten Drug Launches and Prices in Europe
8.3 The Social, Technological, Economic and Political Factors Influencing the Antithrombotic
Drug Market 2014-2024
8.3.1 Social Factors: An Expanding Patient Population and Increasing Awareness
8.3.2 Technological Advances Encourage the Development of Improved Treatment Options
8.3.3 Economic Factors
8.3.3.1 Cost Cutting in the EU and the US
8.3.3.2 Free Trade Within the EU Presents Challenges
8.3.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Antithrombotic
Drugs?
9. Research Interviews
9.1 Interview with Dr Marcelo A. Lima, Research Fellow and Professor of Molecular Biology,
Department of Biochemistry, Universidade Federal de São Paulo, Brazil
9.1.1 Recent Research on a Novel Heparin-Like Compound Derived From Shrimp
9.1.2 Heparin vs. Novel Oral Anticoagulants
9.1.3 Unmet Needs in Brazil and Worldwide
www.visiongain.com

8. Contents
9.1.4 Trends in the Antithrombotic Drug Market
9.2 Interview with Dr Frank Peacock, Professor, Associate Chair and Research Director, Baylor
College of Medicine, Houston, Texas
9.2.1 Warfarin vs. Novel Oral Anticoagulants
9.2.2 The Unmet Needs of the Market
9.2.3 The Antithrombotic R&D Pipeline
9.2.4 Key Market Drivers and Restraints
9.3 Interview with Dr Walter Ageno, Associate Professor of Medicine, Department of Clinical
and Experimental Medicine, University of Insubria, Italy
9.3.1 Unmet Needs
9.3.2 Future Focus of Antithrombotic Therapy
9.3.3 The Antithrombotic R&D Pipeline
9.3.4 Key Market Drivers and Restraints
9.3.5 Opportunities in the Market
9.4 Interview with Dr Jonathan L. Halperin, Professor of Medicine, Director of Clinical Cardiology
Services, Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center,
New York
9.4.1 Unmet Needs
9.4.2 New Findings
9.4.3 Warfarin Replacement
9.4.4 Areas Demanding Attention
9.4.5 Key Market Restraints
10. Conclusions from Our Study
10.1 The World Market for Antithrombotic Drugs 2014-2024
www.visiongain.com

9. Contents
10.1.1 The Decline of Antiplatelet Drugs and the Rise of the Anticoagulants
10.2 The Leading National Markets 2014-2024
10.3 Trends in the Industry
10.3.1 The Market Will Recover From Plavix Decline
10.3.2 The Demand for Antithrombotic Drugs is Increasing Worldwide
10.3.3 Many Drugs Will Face Generic Competition Over the Coming 10 Years
10.3.4 High Barriers to Market Entry and a Limited Pipeline – The Implications
www.visiongain.com

10. Contents
List of Tables
Table 1.1 Currency Exchange Rates, 2012 and 2013
Table 2.1 An Overview of Antithrombotic Drugs by Therapeutic Class, 2014
Table 3.1 The Antithrombotic Drug Market by Therapeutic Class: Revenues ($m) and Market
Shares (%), 2012 and 2013
Table 3.2 The Global Market for Antithrombotic Drugs: Revenue Forecast ($m), 2013-2024
Table 3.3 The Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m)
and Market Shares (%), 2018 and 2024
Table 3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue ($m) and Market
Share (%) Forecasts, 2013-2024
Table 3.5 Antiplatelet Drugs: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 3.6 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2013-2024
Table 3.7 Heparins: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 3.8 Direct Thrombin Inhibitors: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 3.9 Direct Factor Xa Inhibitors: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 3.10 The Warfarin Market: Companies and Year of Introduction
Table 3.11 Vitamin K Antagonists: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 3.12 Fibrinolytics: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.1 The Leading National Markets for Antithrombotic Drugs: Revenues ($m) and Market
Shares (%), 2012 and 2013
Table 4.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues
($m) and Market Shares (%), 2018 and 2024
Table 4.3 The Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m),
2013-2024
www.visiongain.com

11. Contents
Table 4.4 The US Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast,
2013-2024
Table 4.5 The EU5 Market for Antithrombotic Drugs: Revenue Forecasts ($m), 2013-2024
Table 4.6 The German Antithrombotic Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2024
Table 4.7 The French Antithrombotic Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2024
Table 4.8 The UK Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast,
2013-2024
Table 4.9 The Italian Antithrombotic Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2024
Table 4.10 The Spanish Antithrombotic Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2024
Table 4.11 The Japanese Antithrombotic Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2024
Table 4.12 The Chinese Antithrombotic Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2024
Table 4.13 The Brazilian Antithrombotic Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2024
Table 4.14 The Indian Antithrombotic Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2024
Table 4.15 The Russian Antithrombotic Drug Market: Revenue ($m) and Market Share (%)
Forecast, 2013-2024
Table 5.1 The Leading Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2012 and
2013
Table 5.2 The Leading Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares
(%), 2018 and 2024
www.visiongain.com

12. Contents
Table 5.3 The Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2013-2024
Table 5.4 Plavix: Key Facts, 2014
Table 5.5 Plavix: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.6 Lovenox: Key Facts, 2014
Table 5.7 Lovenox: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.8 Pradaxa: Key Facts, 2014
Table 5.9 Pradaxa: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.10 Xarelto: Key Facts, 2014
Table 5.11 Xarelto: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.12 Activase: Key Facts, 2014
Table 5.13 Activase: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.14 Effient: Key Facts, 2014
Table 5.15 Effient: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.16 Aspirin Cardio: Key Facts, 2014
Table 5.17 Aspirin Cardio: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.18 Angiomax: Key Facts, 2014
Table 5.19 Angiomax: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.20 Pletal: Key Facts, 2014
Table 5.21 Pletal: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.22 Aggrenox: Key Facts, 2014
Table 5.23 Aggrenox: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.24 Sandoz’s Enoxaparin Sodium: Key Facts, 2014
Table 5.25 Sandoz’s Enoxaparin Sodium: Revenue ($m) and Market Share (%) Forecast, 20132024
www.visiongain.com

13. Contents
Table 5.26 Fragmin: Key Facts, 2014
Table 5.27 Fragmin: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.28 Arixtra: Key Facts, 2014
Table 5.29 Arixtra: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.30 Brilinta: Key Facts, 2014
Table 5.31 Brilinta: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.32 Eliquis: Key Facts, 2014
Table 5.33 Eliquis: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 6.1 The Antiplatelet Drug R&D Pipeline, 2014
Table 6.2 The Heparins Pipeline, 2014
Table 6.3 The Vitamin K Antagonist Pipeline, 2014
Table 6.4 The Direct Thrombin Inhibitors Pipeline, 2014
Table 6.5 The Direct Factor Xa Inhibitor Pipeline, 2014
Table 6.6 The Fibrinolytics R&D Pipeline, 2014
Table 6.7 Other Antithrombotic Drugs in the Pipeline, 2014
Table 7.1 The Top 10 Companies: Revenues ($m) and Market Shares (%), 2012 and 2013
Table 7.2 Sanofi: Antithrombotic Drug Portfolio, 2014
Table 7.3 Bristol-Myers Squibb: Antithrombotic Drug Portfolio, 2014
Table 7.4 Boehringer Ingelheim: Antithrombotic Drug Portfolio, 2014
Table 7.5 Bayer: Antithrombotic Drug Portfolio, 2014
Table 7.6 Johnson & Johnson: Antithrombotic Drug Portfolio, 2014
Table 7.7 Genentech: Antithrombotic Drug Portfolio, 2014
Table 7.8 The Medicines Company: Antithrombotic Drug Portfolio, 2014
Table 7.9 Otsuka: Antithrombotic Drug Portfolio, 2014
www.visiongain.com

14. Contents
Table 7.10 Eli Lilly: Antithrombotic Drug Portfolio, 2014
Table 7.11 Sandoz: Antithrombotic Drug Portfolio, 2014
Table 8.1 Strengths and Weaknesses of the Antithrombotic Drug Market, 2014
Table 8.2 Opportunities and Threats Facing the Antithrombotic Drug Market, 2014-2024
Table 8.3 Social, Technological, Economic and Political Factors Influencing the Antithrombotic
Drug Market (STEP Analysis), 2014-2024
www.visiongain.com

15. Contents
List of Figures
Figure 2.1 Diagram Depicting the Coagulation Cascade, 2013
Figure 3.1 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2012
Figure 3.2 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2013
Figure 3.3 The Global Market for Antithrombotic Drugs: Revenue Forecast ($m), 2013-2024
Figure 3.4 The Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 3.5 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2018
Figure 3.6 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2024
Figure 3.7 The Antithrombotic Drug Market by Therapeutic Class: Revenue Forecasts ($m),
2013-2024
Figure 3.8 Antiplatelet Drugs: Revenue Forecast ($m), 2013-2024
Figure 3.9 The Antiplatelet Drug Market: Drivers and Restraints, 2014-2024
Figure 3.10 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2013-2024
Figure 3.11 Heparins: Revenue Forecast ($m), 2013-2024
Figure 3.12 The Heparins Market: Drivers and Restraints, 2014-2024
Figure 3.13 Direct Thrombin Inhibitors: Revenue Forecast ($m), 2013-2024
Figure 3.14 The Direct Thrombin Inhibitors Market: Drivers and Restraints, 2014-2024
Figure 3.15 Direct Factor Xa Inhibitors: Revenue Forecast ($m), 2013-2024
Figure 3.16 Direct Factor Xa Inhibitors Market: Drivers and Restraints, 2014-2024
Figure 3.17 Vitamin K Antagonists: Revenue Forecast ($m), 2013-2024
Figure 3.18 The Vitamin K Antagonist Market: Drivers and Restraints, 2014-2024
Figure 3.19 Fibrinolytics: Revenue Forecast ($m), 2013-2024
Figure 3.20 The Fibrinolytics Market: Drivers and Restraints, 2014-2024
www.visiongain.com

16. Contents
Figure 4.1 The Antithrombotic Drug Market by Country: Market Shares (%), 2012
Figure 4.2 The Antithrombotic Drug Market by Country: Market Shares (%), 2013
Figure 4.3 The Antithrombotic Drug Market by Country: Market Shares (%), 2018
Figure 4.4 The Antithrombotic Drug Market by Country: Market Shares (%), 2024
Figure 4.5 Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 20132024
Figure 4.6 The US Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.7 The US Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 4.8 EU5 Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2013-2024
Figure 4.9 EU5 Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 4.10 The German Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.11 The French Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.12 The UK Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.13 The Italian Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.14 The Spanish Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.15 The Japanese Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.16 The Japanese Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 4.17 The Chinese Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.18 The Chinese Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 4.19 The Brazilian Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.20 The Brazilian Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 4.21 The Indian Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.22 The Indian Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 4.23 The Russian Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
www.visiongain.com

17. Contents
Figure 4.24 The Russian Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 5.1 The Leading Antithrombotic Drugs: Market Shares (%), 2012
Figure 5.2 The Leading Antithrombotic Drugs: Market Shares (%), 2013
Figure 5.3 The Leading Antithrombotic Drugs: Market Shares (%), 2018
Figure 5.4 The Leading Antithrombotic Drugs: Market Shares (%), 2024
Figure 5.5 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2013-2024
Figure 5.6 Plavix: Revenue Forecast ($m), 2013-2024
Figure 5.7 Lovenox: Revenue Forecast ($m), 2013-2024
Figure 5.8 Pradaxa: Revenue Forecast ($m), 2013-2024
Figure 5.9 Xarelto: Revenue Forecast ($m), 2013-2024
Figure 5.10 Activase: Revenue Forecast ($m), 2013-2024
Figure 5.11 Effient: Revenue Forecast ($m), 2013-2024
Figure 5.12 Aspirin Cardio: Revenue ($m) Forecast, 2013-2024
Figure 5.13 Angiomax: Revenue Forecast ($m), 2013-2024
Figure 5.14 Pletal: Revenue Forecast ($m), 2013-2024
Figure 5.15 Aggrenox: Revenue Forecast ($m), 2013-2024
Figure 5.16 Sandoz’s Enoxaparin Sodium: Revenue Forecast ($m), 2013-2024
Figure 5.17 Fragmin: Revenue Forecast ($m), 2013-2024
Figure 5.18 Arixtra: Revenue Forecast ($m), 2013-2024
Figure 5.19 Brilinta: Revenue Forecast ($m), 2013-2024
Figure 5.20 Eliquis: Revenue Forecast ($m), 2013-2024
Figure 6.1 An Overview of the R&D Pipeline for Antithrombotic Drugs, 2014
Figure 7.1 The Top 10 Leading Companies: Market Shares (%), 2012
Figure 7.2 The Top 10 Leading Companies: Market Shares (%), 2013
www.visiongain.com

18. Contents
Figure 10.1 The Global Antithrombotic Drug Market by Therapeutic Class: Comparison of
Revenues ($m), 2013-2024
Figure 10.2 The National Markets for Antithrombotic Drugs: Comparison of Revenues ($m),
2012, 2018 and 2024
www.visiongain.com

19. Contents
Companies ListedOther Organisations Mentioned
Companies and
Abbott Laboratories
Ablynx
Aché
AdvanceCor
Alchemia
Amneal Pharms
Amphastar Pharmaceuticals
App Pharmaceuticals
ARCA Biopharma
Armetheon
ARYx Therapeutics
Asahi Kasei Pharma America
Aspen
Astellas Pharma
AstraZeneca
Barr Laboratories
Bayer
Baylor College of Medicine, Houston, Texas
Bharat Biotech
BioVascular
Boehringer Ingelheim
Bristol-Myers Squibb
Canyon Pharmaceuticals
www.visiongain.com

20. Contents
Committee on Medicinal Products for Human Use (CHMP)
CSL Behring
Daiichi Sankyo
Dexa Medica Group
Diakron Pharmaceuticals
Dr. Reddy’s Laboratories
DuPont Merck
Eisai
Eli Lilly
EMS
Endo Laboratories
ESP Pharma
Eurofarma
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Fournier Pharma
Gate Pharmaceuticals
Genentech
German Institute for Quality and Efficiency in Health Care (IQWiG)
GlaxoSmithKline (GSK)
Grifols Therapeutics
Hoechst Marion Roussell
Hospira
Hypermarcas
www.visiongain.com

21. Contents
Indonesia University
Invagen Pharms
IPCA Labs
Isis Pharmaceuticals
Johns Hopkins Medicine
Johnson & Johnson (J&J)
Kowa
Kyowa Hakko
Lee’s Pharmaceutical
LG Life Sciences
LIMES Institute
Lundbeck
Merck & Co.
Mitsubishi
Mitsubishi Tanabe Pharma
Momenta Pharmaceuticals
Mylan Pharmaceuticals
National Health Service (NHS)
National Institute for Health and Care Excellence (NICE)
Novartis
Nuvelo
Organon
Otsuka Pharmaceutical Company
Pfizer
www.visiongain.com

22. Contents
Pharmaceutical and Medical Devices Agency (PMDA)
Pharmacia
PLIVA
PLx Pharma
Portola Pharmaceuticals
Pozen
Regado Biosciences
Roche
Sandoz
Sanofi
Sun Pharmaceuticals
Takeda
Taro
Teva Pharmaceuticals
The Medicines Company
ThromboGenics
Tianjin Medical
Tufts Medical Center
Unified Health System (SUS)
Universidade Federal de São Paulo
University General Hospital
University of Insubria (Italy)
Upjohn AB
US Department of Justice
www.visiongain.com

23. Contents
USL Pharma
Virginia Commonwealth University
World Health Organization (WHO)
Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York
Zydus Cadila
www.visiongain.com

24. Antithrombotic Drugs: World Industry and
Market Prospects 2014-2024
Between 2012 and 2018, the Chinese antithrombotic drug market will expand at a CAGR of 5.87%.
From 2021 onwards, the market will see declining revenue as a result of generic versions of the
market leading drugs flooding the market. Between 2018 and 2024, the Chinese market will
contract at a CAGR of -1.78%. This contraction will be less than that of the developed nations,
since the Chinese market is not dominated by branded products. In 2024, sales of antithrombotic
drugs in China will generate $1,374m, accounting for 7.9% of the global market.
Figure 4.18 The Chinese Antithrombotic Drug Market: Drivers and Restraints, 20142024
Restraints
Drivers
•
Increasing patient population.
•
IP protection remains a concern.
•
Severity of indicated conditions.
•
Market is dominated by low-cost
generics.
•
Expansion of government healthcare
coverage.
Source: visiongain 2014
4.8 The Brazilian Antithrombotic Drug Market 2014-2024: Strong
Growth as Universal Healthcare Coverage is Expanded
In 2013, the Brazilian antithrombotic drug market generated $523m, accounting for 3% of the
global market. In that year, the market saw 11% growth, driven by the increasing up take of Plavix
as well as other antithrombotic drugs. Cardiovascular diseases are the largest cause of death in
Brazil. As such, the demand for antithrombotic drugs is high. Generic drugs have a strong
presence in Brazil, accounting for 17% of that pharmaceutical market in 2012.
The Brazilian government’s policies have helped to build the domestic generics industry, with
EMS, Hypermarcas, Aché and Eurofarma prominent companies. This domestic industry is
improving access to healthcare for the Brazilian population, by producing affordable drugs. That is
www.visiongain.com
Page 84

25. Antithrombotic Drugs: World Industry and
Market Prospects 2014-2024
a large population, and as access improves, demand for pharmaceuticals is increasing; the generic
drugs sector is the fastest growing of the Brazilian pharmaceutical market.
At present, a significant proportion of the population remain under-served by the public health
service. However, the government strives to widen access to health services and medicines,
fuelling growth in the market over the forecast period. At the same time, affluent people are
improving their cover with private healthcare. This is resulting in an increasing demand for branded
drugs. To help meet this demand, increasingly the government establishes technology-transfer
deals to bring the production of patented drugs into the country. This will also fuel growth in the
antithrombotic drug market. Multinational leaders in Brazil include Sanofi, Novartis, Roche and
Merck & Co. There is much interest from multinational pharma companies in trading with and in
Brazil.
Table 4.13 The Brazilian Antithrombotic Drug Market: Revenue ($m) and Market
Share (%) Forecast, 2013-2024
Market Share (%)
Revenue ($m)
AGR (%)
CAGR (%)
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
2.60 3.00 3.07 3.12 3.17 3.20 3.25 3.30 3.35 3.40 3.45 3.50 3.60
471 523 550 576 605 630 663 683 702 688 674 653 626
11
5
5
5
4
5
3
3
-2
-2
-3
-4
5.87
-0.95
Source: visiongain 2014; CAGR values for year ranges 2012-2018 and 2018-2024
Figure 4.19 The Brazilian Antithrombotic Drug Market: Revenue Forecast ($m), 20132024
800
700
Revenue ($m)
600
500
400
300
200
100
0
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Year
Source: visiongain 2014
www.visiongain.com
Page 85